Search
Terpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnIt was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate … Terpin hydrate is an expectorant, commonly used to loosen mucus and ease congestion in patients presenting with acute or chronic bronchitis, and related pulmonary conditions.
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalIt is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Strontium chloride Sr-89
go.drugbank.com/drugs/DB09498ApprovedIt is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. … Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer.[A31264] Bone metastases is a common and severe complication presented in advanced stages of the disease.
Acemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigational[A31352] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[T50] It was developed by E. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and
Apadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in ADAMTS13 is responsible for the microangiopathic complications associated with cTTP
Almasilate
go.drugbank.com/drugs/DB13595ApprovedAlmasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.
Ferric maltol
go.drugbank.com/drugs/DB15598ApprovedInvestigational[A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate
Tetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigationalTetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]
Plozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigational[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.